AI IntelligenceMar 29, 2026Secondary Market
Article
AGL
BTIG cuts its price target on Humacyte (HUMA) but maintains a Buy rating, citing a larger long-term opportunity despite near-term challenges. The stock movement reflects this mixed analyst sentiment.
Data Cube AI EditorialSource: Yahoo Finance
01
Source Brief
BTIG cuts its price target on Humacyte (HUMA) but maintains a Buy rating, citing a larger long-term opportunity despite near-term challenges. The stock movement reflects this mixed analyst sentiment.
02